SideROS aims to improve the conditions of patients affected by life-threatening diseases lacking of effective treatment.
SideROS bridges innovative research on iron-targeting chemical compounds and drug candidate discoveries to target persister cancer cells, refractory to conventional treatments and associated to metastasis and relapse. The role of iron is ubiquitous whatever the origin of cancer cells, suggesting that our small molecules can target various types of cancer.
SideROS was founded in January 2019 based on the research from Dr Raphaël Rodriguez, a world renowned scientist devoted to understand persister cancer cells biology, the role of iron homeostasis in those cells and know how to target them and Robin Rivaton, as business advisor. The company is incubated at ICM since September 2019.
SideROS aims to eradicate cancer cells responsible of relapses and metastates and to improve the conditions of patients affected by life-threatening diseases lacking of effective treatment.
at Curie Institute, performed his PhD studies under the supervision of Prof Sir Jack E. Baldwin and Prof Maurice Santelli at the University of Oxford and in Marseille, where he completed the synthesis of structurally complex natural products by means of pericyclic processes. He joined The University of Cambridge in November 2005 as a postdoctoral fellow, together with Prof. Steve Jackson (Gurdon Institute, UK), they firmly established a link between G-quadruplex DNA structures and genomic instability. Raphaël joined the CNRS as a group leader in 2012 and was promoted Director of Research at Institut Curie in 2017. His recent achievements include the development of the anti-aging small molecule remodelin, the first chemical synthesis of the complex natural product marmycin and the iron metabolism targeting drug ironomycin. His group has recently elucidated the mechanism of action of salinomycin against persister cancer cells and identified a role of iron in the maintenance of these cells.
Awards 2019: Tetrahedron Young Investigator Award
2019: i-Lab Award for the company SideROS
2019: Grand Prix de l’Institut de France ‘Charles Defforey’
2019: SUNRISE Cancer Stem Cell Award
2019: Grand Prix du Collège de France (Lacassagne)
2017: Fellow of the Royal Society of Chemistry (FRSC)
is a VC Investor in Smart City (IDInvest), author (8 books), former consultant (BCG, Paris Airports), independant board member (Sogeprom, Manuloc)
Dr Lucie Mondoulet, CEO , 11 years experience in biotechnology at the direction of R&D department from discovery to clinical program.
Nathalie Donne, 15 years experience in biotechnology at the direction of BD & alliance management department .
Dr Laurent Martin, 25 years experience in Pharma & biotechnology at the direction of regulatory affairs and global development department.
SideROS won the iLAB 2019 National competition , which supports the creation of innovative technology companies.
SideROS selected for the 2020 EIT Health Headstart program , meaning access to mentoring, business and financial support and access to valuable contacts.
SideROS supported by BPI Frenchtech subsidy in 2019 to support its launch and development.